ArticleFuture oncology (London, England)2026

A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study design.

Naureen Starling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.